EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Hospital at Home for BCMA-Directed Bispecific Antibodies in Multiple Myeloma: A Multicenter Real-World Feasibility and Safety Study

Jeremie Zerbit, Marguerite Vignon, Guillemette Fouquet, Marion Detroit, Sylvain Choquet, Laurent Garderet, Olivier Hermine, Clarisse Cazelles, Laurent Frenzel, Mohamad Mohty, Zoe Van De Wyngaert, Stephanie Harel und 7 weitere

Clinical Lymphoma Myeloma and Leukemia · 2026-10 · 26 (10) · e1178-e1186

DOI: 10.1016/j.clml.2026.07.017 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026-10. Verfasst von Jeremie Zerbit und 18 weiteren Autor:innen. Beteiligte Einrichtung: Hospital at Home, Greater Paris University Hospitals (AP-HP), Paris, France. Electronic address: jeremie.zerbit@aphp.fr. Hauptthemen laut MEDLINE: Antibodies, Bispecific, B-Cell Maturation Antigen, Multiple Myeloma. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: BCMA-directed bispecific antibodies (BsAbs) have improved outcomes in relapsed/refractory multiple myeloma (rrMM), but early toxicities often require close hospital monitoring. We evaluated the feasibility and safety of BsAb administration through a Hospital at Home (HaH) model. PATIENTS AND METHODS: We conducted a retrospective multicenter real-world study including consecutive triple-class or penta-refractory rrMM patients treated with teclistamab or elranatamab between July 2022 and January 2024. Outcomes of patients receiving at least one HaH administration were descriptively evaluated alongside those of patients managed exclusively in conventional hospital settings. Safety and survival outcomes were assessed using a 68-day landmark analysis corresponding to the median time to HaH transition. RESULTS: Among 201 patients, 46 received HaH administration and 155 were managed exclusively in hospital. Baseline characteristics were broadly comparable, with differences consistent with clinical selection for HaH, notably performance status. After the landmark, no grade ≥ 3 infection was observed in the HaH group, whereas severe infectious events continued to accumulate in the No HaH group. Rates of post-landmark bacterial, respiratory, opportunistic, and fungal infections were broadly similar across care pathways. Overall survival, progression-free survival, and time to treatment failure did not suggest inferior outcomes in the HaH group. CONCLUSION: In selected rrMM patients, HaH administration of BsAb therapy was feasible and was not associated with inferior survival outcomes. The lower observed rate of severe infections supports further evaluation of this model, while accounting for clinical selection and supportive-care differences.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificB-Cell Maturation AntigenMultiple MyelomaAgedAged, 80 and overFemaleHumansMaleMiddle AgedFeasibility StudiesRetrospective Studies

Stichwörter der Autor:innen

Infections

Substanzen

Antibodies, BispecificB-Cell Maturation Antigen

Autor:innen und Institutionen

  • Hospital at Home, Greater Paris University Hospitals (AP-HP), Paris, France. Electronic address: jeremie.zerbit@aphp.fr.
  • Hematology, Cochin Hospital, Greater Paris University Hospitals (AP-HP), Paris, France.
  • Hematology, Hospital Sud Francilien, Corbeil-Essonnes, France.
  • Pharmacy, Gustave Roussy, Villejuif, France.
  • Hematology, Pitié- Salpêtrière Hospital, Greater Paris University Hospitals (AP-HP), Paris, France.
  • Hematology, Necker Hospital, Greater Paris University Hospitals (AP- HP), Paris, France.

Zitieren

APA

Zerbit, J., Vignon, M., Fouquet, G., Detroit, M., Choquet, S., Garderet, L., Hermine, O., Cazelles, C., Frenzel, L., Mohty, M., Van De Wyngaert, Z., Harel, S., Rahme, R., Collier, M., Moufle, F., Leclaire, C., Bouscary, D., Moreau, P., & Winer, R. (2026). Hospital at Home for BCMA-Directed Bispecific Antibodies in Multiple Myeloma: A Multicenter Real-World Feasibility and Safety Study. Clinical Lymphoma Myeloma and Leukemia, 26(10), e1178-e1186. https://doi.org/10.1016/j.clml.2026.07.017

Vancouver

Zerbit J, Vignon M, Fouquet G, Detroit M, Choquet S, Garderet L, et al. Hospital at Home for BCMA-Directed Bispecific Antibodies in Multiple Myeloma: A Multicenter Real-World Feasibility and Safety Study. Clinical Lymphoma Myeloma and Leukemia. 2026;26(10):e1178-e1186. doi:10.1016/j.clml.2026.07.017

BibTeX
@article{Zerbit2026,
  author = {Zerbit, Jeremie and Vignon, Marguerite and Fouquet, Guillemette and Detroit, Marion and Choquet, Sylvain and Garderet, Laurent and Hermine, Olivier and Cazelles, Clarisse and Frenzel, Laurent and Mohty, Mohamad and Van De Wyngaert, Zoe and Harel, Stephanie and Rahme, Ramy and Collier, Mathis and Moufle, Frederique and Leclaire, Clement and Bouscary, Didier and Moreau, Philippe and Winer, Romain},
  title = {Hospital at Home for BCMA-Directed Bispecific Antibodies in Multiple Myeloma: A Multicenter Real-World Feasibility and Safety Study},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2026},
  volume = {26},
  number = {10},
  pages = {e1178--e1186},
  doi = {10.1016/j.clml.2026.07.017}
}
Kostenlos starten →